NCT04385251 (ICOS) is a clinical trial of Data Collection in COVID, sponsored by University of Minnesota.

Who is sponsoring NCT04385251?

NCT04385251 is sponsored by University of Minnesota.

What drugs are being tested in NCT04385251?

Interventions in NCT04385251: Data Collection.

What condition does NCT04385251 study?

NCT04385251 studies COVID, COVID19, SARS-CoV 2, Dyspnea.

Is NCT04385251 still recruiting?

NCT04385251 is currently completed. Last updated 16 August 2022.

Last reviewed 2022-08-16 · How we verify

NCT04385251: ICOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

International SARS-CoV-2 (COVID-19) Infection Observational Study

Completed Last updated 16 August 2022

What this trial tests

trial testing Data Collection in COVID in 11,973 participants. Completed in 31 January 2022.

Timeline

18 June 2020

Primary endpoint
31 January 2022

31 January 2022

Quick facts

Lead sponsor	University of Minnesota
Status	Completed
Study type	OBSERVATIONAL
Enrollment	11,973
Start date	18 June 2020
Primary completion	31 January 2022
Estimated completion	31 January 2022
Sites	4 locations across Denmark, Argentina, United Kingdom, United States

Drugs / interventions tested

Data Collection — full drug profile →

Conditions studied

COVID — all drugs for COVID →
COVID19 — all drugs for COVID19 →
SARS-CoV 2 — all drugs for SARS-CoV 2 →
Dyspnea — all drugs for Dyspnea →

Sponsor

University of Minnesota

Who can join

18 and older, any sex, with COVID or COVID19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-CoV-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Maintaining international research collaborations in the setting of a pandemic: Approach in Indonesia.
Karyana M, Kosasih H, Neal AT, Lau CY. · · 2021 · cited 3× · PMID 34326986 · DOI 10.7189/jogh.11.03087
International clinical research networks - a collaborative approach for pandemic preparedness and response: The case of The Mexican Emerging Infectious Disease Clinical Research Network (LaRed).
Ruiz-Palacios GM, Regalado-Pineda J, Montenegro-Liendo A, Guerra-de-Blas PDC, et al · · 2023 · PMID 37441774 · DOI 10.7189/jogh.13.03031

Verify or expand the search:

Other trials of Data Collection

Trials testing the same drug.

NCT06868459 — Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Mul · enrolling by invitation
NCT05395936 — Mastectomy Flap Temperature Study · NA · terminated
NCT05616130 — Pathological Myeloid Activation After Sepsis and Trauma · recruiting
NCT04541212 — Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast C · active not recruiting
NCT04850105 — A Non-interventional Cohort Safety Study of Patients With hATTR-PN · recruiting

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other University of Minnesota trials

Trials by the same sponsor.

NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04385251 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
Last refreshed: 16 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04385251.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing